Clinical Trial Update: Guttmann NeuroRecovery - Viability, Safety, and Efficacy of Intrathecal Wharton's Jelly Mesenchymal Stem Cells and Transcutaneous Spinal Cord Stimulation in Chronic Spinal Cord Injury Rehabilitation [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating intrathecal Wharton's Jelly mesenchymal stem cells with transcutaneous spinal cord stimulation for chronic spinal cord inj…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Cord Disease
• Spinal Cord Injury
• Traumatic Spinal Cord Injury

Drugs mentioned

• Transcutaneous Spinal Cord Stimulation (transcutaneous spinal cord stimulation)
• Wharton's Jelly Mesenchymal Stem Cells (mesenchymal stem cells)

Snippet

Sponsor: Institut Guttmann | Conditions: Spinal Cord Injuries (SCI), Spinal Cord Injury | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING